JP2019501125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501125A5 JP2019501125A5 JP2018525654A JP2018525654A JP2019501125A5 JP 2019501125 A5 JP2019501125 A5 JP 2019501125A5 JP 2018525654 A JP2018525654 A JP 2018525654A JP 2018525654 A JP2018525654 A JP 2018525654A JP 2019501125 A5 JP2019501125 A5 JP 2019501125A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- heteroaryl
- substituted
- bicyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C1=CC(N(*)*)=I[n]2c1ncc2C(N*)=O Chemical compound *C1=CC(N(*)*)=I[n]2c1ncc2C(N*)=O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256784P | 2015-11-18 | 2015-11-18 | |
| US62/256,784 | 2015-11-18 | ||
| US201662404827P | 2016-10-06 | 2016-10-06 | |
| US62/404,827 | 2016-10-06 | ||
| PCT/US2016/062396 WO2017087590A1 (en) | 2015-11-18 | 2016-11-17 | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501125A JP2019501125A (ja) | 2019-01-17 |
| JP2019501125A5 true JP2019501125A5 (https=) | 2019-12-26 |
| JP6843135B2 JP6843135B2 (ja) | 2021-03-17 |
Family
ID=57472068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525654A Active JP6843135B2 (ja) | 2015-11-18 | 2016-11-17 | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10479793B2 (https=) |
| EP (1) | EP3377496B1 (https=) |
| JP (1) | JP6843135B2 (https=) |
| KR (1) | KR102782807B1 (https=) |
| CN (1) | CN108473500B (https=) |
| ES (1) | ES2828733T3 (https=) |
| WO (1) | WO2017087590A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015342883B2 (en) | 2014-11-06 | 2020-07-02 | Bial - R&D Investments, S.A. | Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders |
| WO2016073889A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| HRP20240644T1 (hr) | 2014-11-06 | 2024-08-02 | Bial-R&D Investments, S.A. | Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja |
| EP3440081A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US11192892B2 (en) | 2016-04-06 | 2021-12-07 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
| SG11201809693SA (en) | 2016-05-05 | 2018-11-29 | Lysosomal Therapeutics Inc | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| ES2902995T3 (es) | 2016-10-07 | 2022-03-30 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| EP3541817B1 (en) * | 2016-11-17 | 2020-12-23 | Bristol-Myers Squibb Company | Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha |
| KR102717819B1 (ko) * | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
| AU2019234574A1 (en) | 2018-03-12 | 2020-09-03 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| JP7179161B2 (ja) * | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| TWI800696B (zh) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| TWI752400B (zh) | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| CN120865208A (zh) * | 2019-01-23 | 2025-10-31 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| US20220135567A1 (en) * | 2019-02-07 | 2022-05-05 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| CN114222744B (zh) * | 2019-03-05 | 2024-06-25 | 百时美施贵宝公司 | 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物 |
| CA3132632A1 (en) * | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| TWI810520B (zh) * | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
| WO2021162944A1 (en) | 2020-02-12 | 2021-08-19 | Eli Lilly And Company | Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives |
| KR20230019507A (ko) * | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
| WO2021220183A1 (en) * | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | Imidazopyrimidines as modulators of il-17 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN115916207A (zh) * | 2020-08-20 | 2023-04-04 | 轶诺(浙江)药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| AU2021345181A1 (en) * | 2020-09-16 | 2023-05-04 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| CN117043164A (zh) * | 2021-01-19 | 2023-11-10 | 安锐生物医药科技(广州)有限公司 | 咪唑并哒嗪或吡唑并嘧啶化合物和组合物 |
| EP4308556A4 (en) | 2021-03-16 | 2025-02-19 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| CN118580191A (zh) * | 2022-01-28 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体 |
| WO2025168035A1 (zh) * | 2024-02-07 | 2025-08-14 | 合肥羿科医药有限公司 | 杂环类化合物、其药物组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| EP2125819B1 (en) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| EP2217601A1 (en) * | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| RU2014120166A (ru) * | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина |
| RU2014140739A (ru) | 2012-03-09 | 2016-04-27 | Лексикон Фармасьютикалз, Инк. | Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
-
2016
- 2016-11-17 US US15/776,094 patent/US10479793B2/en active Active
- 2016-11-17 KR KR1020187016633A patent/KR102782807B1/ko active Active
- 2016-11-17 JP JP2018525654A patent/JP6843135B2/ja active Active
- 2016-11-17 EP EP16805656.2A patent/EP3377496B1/en active Active
- 2016-11-17 WO PCT/US2016/062396 patent/WO2017087590A1/en not_active Ceased
- 2016-11-17 CN CN201680079065.7A patent/CN108473500B/zh active Active
- 2016-11-17 ES ES16805656T patent/ES2828733T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501125A5 (https=) | ||
| JP2019530699A5 (https=) | ||
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| JP2016532715A5 (https=) | ||
| JP2016516043A5 (https=) | ||
| JP2016514159A5 (https=) | ||
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| JP2017508782A5 (https=) | ||
| JP2017501237A5 (https=) | ||
| JP2017071634A5 (https=) | ||
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| EP3489232A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| JP2019522055A5 (https=) | ||
| JP2016513696A5 (https=) | ||
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| PH12020500327A1 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| JP2015522650A5 (https=) | ||
| JP2014525420A5 (https=) | ||
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2016507581A5 (https=) | ||
| JP2015536947A5 (https=) | ||
| JP2019535723A5 (https=) | ||
| JP2015504081A5 (https=) |